Table 1

Relationship between expression of nuclear phosphorylated signal transducer and activator of transcription 3 (p-STAT3) and clinicopathological parameters among 104 patients with advanced rectal cancer

VariableAll patientsp-STAT3
+ (n=39)− (n=65)p Value
Age (years)
 Median66.065.066.00.36
 Range37.0–80.037.0–78.040.0–80.0
 Mean (SD)64.4 (8.9)64.1 (8.3)63.9 (9.5)
Sex, no. (%)
 Male76 (73.1)31 (79.5)45 (69.2)0.36
 Female28 (26.9)8 (20.5)20 (30.8)
Distance to anal verge, no. (%)
 0–5 cm53 (51.0)19 (48.7)34 (52.3)0.62
 6–10 cm43 (41.3)18 (46.2)25 (38.5)
 >10 cm8 (7.7)2 (5.1)6 (9.2)
Treatment, no. (%)
 RT32 (30.8)12 (30.8)20 (30.8)0.52
 RT/CT31 (29.8)9 (23.1)22 (33.8)
 RT + adjuvant CT20 (19.2)10 (25.6)10 (15.4)
 RT/CT + adjuvant CT21 (20.2)8 (20.5)13 (20.0)
cTNM stage*
 T3103 (99.0)38 (97.4)65 (100.0)NA
 T41 (1.0)1 (2.6)0
Histological type, no. (%)
 Adenocarcinoma98 (94.2)37 (94.9)61 (93.1)NA
 Mucinous5 (4.8)1 (2.3)4 (6.1)
 Signet ring1 (1.0)1 (2.3)0
Tumour differentiation, no. (%)
 Well differentiated47 (48.0)14 (37.8)33 (54.1)0.17
 Moderately differentiated50 (51.0)23 (62.2)28 (44.2)
 Poorly differentiated1 (1.0)01 (1.6)
Lymph node metastasis, no. (%)
 Absent67 (64.4)22 (59.5)45 (77.8)0.18
 Present31 (29.8)15 (40.5)16 (26.2)
Venous invasion, no. (%)
 Negative68 (65.4)24 (70.6)44 (83.0)0.19
 Positive19 (18.3)10 (29.4)9 (17.0)
Perineural invasion, no. (%)
 Negative66 (63.5)23 (67.6)43 (81.1)0.2
 Positive21 (20.2)11 (32.3)10 (18.9)
Lymphatic invasion, no. (%)
 Negative65 (62.5)23 (69.7)42 (79.2)0.44
 Positive20 (19.2)10 (30.3)10 (20.7)
  • * Tumour staging was clinical, if available, and was otherwise determined by endorectal ultrasonography.

  • RT, radiotherapy; CT, chemotherapy; NA, not applicable.